UnknownNot Applicable

Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta

Egypt150 participantsStarted 2017-01-01

Plain-language summary

The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.

Who can participate

Age range20 Years – 39 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * pregnant women with history of scarred uterus * plcenta previa covering the scar of previous caesarean section as diagnosed by 2DU/S * Gestational age from 28wks to full term Exclusion Criteria: * pregnant women with fetus with congenital anomalies * pregnant women with ovarian swelling * pregnant women with medical disease

What they're measuring

Maternal serum alpha-fetoprotein

Timeframe: From 28weeks to 37 weeks

Trial details

NCT IDNCT04082507

Sponsorrasha medhat abdul-hady

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-08-30

View on ClinicalTrials.gov More Placenta Accreta trials